Lofexidine and naloxone in the management of opiate dependence: increasing choice. by Long, Jean
The Irish EU presidency will oversee significant developments in relation to the
drugs issue, with preliminary discussions taking place on the next iteration of
the EU’s drugs strategy, and the first meeting of national drugs co-ordinators
from the 25 members states of the newly-enlarged Union.
EU drugs strategy conference
On 10–11 May a closed conference will be hosted by the Department of
Justice, Equality and Law Reform in Dublin Castle to lay the groundwork for the
development of a new EU Drugs Strategy 2005–2010. The main targets of the
existing EU Drugs Strategy 2000–2004 are:
■ to reduce significantly the prevalence of illicit drug use, as well as new
recruitment to it, particularly among young people under 18 years of age
■ to reduce substantially the incidence of drug-related health damage and the
number of drug-related deaths
■ to increase substantially the number of successfully treated addicts
■ to reduce substantially the availability of illicit drugs
■ to reduce substantially the number of drug-related crimes
■ to reduce substantially money laundering and illicit trafficking of precursors
The Strategy is underpinned by the EU Action Plan on Drugs 2000–2004, which
transposes the Strategy into concrete actions, and provides both a guide to specific
actions to achieve the Strategy and a solid base for the evaluation of the Strategy. 
A steering group has been established to oversee the final evaluation of the EU
Drugs Strategy, and is due to report by the end of 2004. The Dublin conference,
entitled ‘EU Drugs Strategy – the Way Forward’, will, among other matters,
address the issue of involving civil society in the development of EU drugs policy. 
National drugs co-ordinators’ meeting
On 15 June, six weeks after the accession of 10 new member states to the EU, the
Department of Community, Rural and Gaeltacht Affairs will host a meeting of the
25 EU national drugs co-ordinators in Clontarf Castle. The 2003 Annual Report of
the European Monitoring Centre for Drugs and Drug Abuse (EMCDDA) on the
drug situation in EU acceding and candidate countries noted that enlargement will
present considerable challenges in terms of increased opportunities for drug
trafficking in the EU, escalating drug use within the new member states and the
spread of infectious diseases. As well as posing challenges, it was noted at the
launch of the EMCDDA Report, that enlargement will present ‘a unique
opportunity to benefit from closer cooperation in the drugs area’ (see Drugnet
Ireland 9, September 2003, for a full account of the Report). (Brigid Pike)
For further information, see:
Irish EU Presidency:
www.eu2004.ie
EU Drugs Strategy 2000–2004:
www.europa.eu.int/comm/external_relations/drugs/strat00_04.pdf
EU Action Plan on Drugs 2000–2004:
www.europa.eu.int/comm/external_relations/drugs/ap00_04.pdf
Annual Report on The State of the Drugs Problem in the Acceding and Candidate
Countries to the EU:
www.candidates.emcdda.eu.int/download/candidates_ar2003-en.pdf
contents
Welcome to Issue 10 of Drugnet Ireland. Drugnet
Ireland is the newsletter of the Drug Misuse Research
Division of the Health Research Board. The role of
this publication is to disseminate information, news
and research findings among those involved in the
drugs area in Ireland.
Groundwork for new EU
Drugs Strategy to be laid
during Irish presidency
Drug Misuse Research Division
Health Research Board
Holbrook House, Holles Street,
Dublin 2, Ireland  
t +353 1 6761176 
f +353 1 6618567  
e dmrd@hrb.ie  
w www.hrb.ie
drugnet Ireland 
Issue 10, March 2004Newsletter of the Drug Misuse Research Division
page 1 Groundwork for new EU Drugs Strategy to
be laid during Irish presidency
page 2 New report on cocaine use in Ireland
page 3 Drug seizures down by thirty-nine per cent
page 5 National Drugs Awareness Campaign hits
the road
Clients’ satisfaction with methadone
services
page 6 Final phase of National Alcohol Awareness
Campaign
Binge drinking and drinking-related harm:
a European comparison
page 8 Reclassification of cannabis in the UK
page 9 Opportunities to provide successful
treatment for hepatitis C in drug treatment
centres
Hepatitis C becomes a notifiable disease
Hepatitis C explained
page 10 Calls for extended surveillance system for
hepatitis B and hepatitis C
Lofexidine and naloxone in the
management of opiate dependence:
increasing choice
page 12 Multi-dimensional approach required to
prevent overdose
page 13 EDDRA Column
page 14 Tommy Larkin 1951-2004. An appreciation
National Documentation Centre, first year 
page 15 From Drugnet Europe
Drugs in Focus – Policy Briefings
page 16 Prevnet Conference
page 17 Recent publications
page 20 Upcoming events
In December 2003, the National Advisory
Committee on Drugs (NACD) published a report
entitled An overview of cocaine use in Ireland.1 This
report provides baseline information on cocaine, its
use and treatment options.
The authors provide background information on the
origins of cocaine, which is derived from coca
bushes that grow mainly in South America. As the
authors state, in Ireland, it is illegal to produce,
possess or supply the drug except on prescription.
When taken, cocaine heightens sensations of sight,
sound and smell, as well as making the user feel
more energetic, talkative, alert and euphoric.
Chronic use of cocaine can lead to the development
of mental health problems (for example, paranoia,
hallucinations, anxiety attacks and agitation). The
authors point out that repeated snorting of cocaine
damages the membranes that line the nose. In
addition, use of this drug can also lead to cardio-
vascular complications. Furthermore, if cocaine is
injected, then complications such as abscesses and
blood-borne viral infection may occur. 
The authors describe a small but increasing trend in
cocaine use in Ireland. The first general population
survey designed to calculate the prevalence of drug
use in Ireland was carried out by the NACD in 2003.
It found that three per cent of the adult population
(15 to 64 years) reported using cocaine (powder) in
their lifetime. The highest lifetime prevalence rate
(5%) of cocaine use reported was among young
persons between 15 and 24 years. SLAN carried out
a population survey in 1998 and found that just
under two per cent of males and 0.6 per cent of
females aged 18-64 had used cocaine in the previous
year. In 2002 the rate among males had increased to
three per cent and among females had more than
trebled to almost two per cent. Data from the
National Drug Treatment Reporting System (NDTRS)
also highlighted an increasing trend in cocaine use.
The number of treatment contacts who reported
cocaine as their main problem drug increased from
25 in 1996 to 76 in 2000. In addition, the number
who reported cocaine as their second problem drug
increased substantially, from 121 in 1996 to 504 in
2000. In line with this, the number of cocaine-
related offences increased substantially, from 11 in
1990 to 297 in 2001. Although, as a proportion of
all drug-related offences, cocaine-related offences
remain relatively low at three per cent in comparison
to offences relating to cannabis (60% approximately)
and ecstasy (27% approximately). 
It is difficult to ascertain the nature of cocaine use
in Ireland as very few studies have explored this
issue in depth. Paula Mayock’s study for the Health
Research Board in 2001 provided information on
the nature of recreational cocaine use. The vast
majority of recreational users took cocaine orally or
intranasally and consumed the drug at weekends. It
was of note that recreational users did not consider
their drug consumption damaging or problematic.
Mayock reported that the nature and extent of
cocaine use was
likely to differ
substantially
between her study
group and opiate
users. However, the
author stated, there
was little
understanding of the
nature of cocaine
use among opiate
users. As Mayock
argued, this
information was
essential in order to
increase service
providers’ knowledge and awareness of the health
risks associated with this drug.
As part of the overview, the NACD commissioned
two studies in two different settings so as to explore a
wider spectrum of cocaine use in Dublin. The first
study conducted by UISCE (Union for Improved
Services, Communication and Education) used a
purposive sampling technique in that interviewers
used their networks and contacts to approach people
they thought likely to be cocaine users. Merchant’s
Quay Ireland conducted the second study. They
surveyed 100 clients who presented for treatment at
their health promotion unit and who had used
cocaine or crack in the previous year. The
respondents’ average age of first cocaine use was
similar in the UISCE study and the Merchant’s Quay
study, 21 and 22 years respectively. In both studies
almost half of the respondents used cocaine on a
weekly basis. Twenty per cent of respondents in the
Merchant’s Quay study reported using cocaine on a
daily basis, while this figure doubled to 40 per cent in
the UISCE study. The discrepancy in the two figures
may be due to the fact that the majority of
respondents in the Merchant’s Quay study (83%)
reported using heroin in addition to cocaine, with
almost three-fifths reporting heroin as their main
problem drug. In contrast, just over two-fifths of
cocaine users in the UISCE study reported heroin use.
Participants in both studies reported high levels of
polydrug use. A lower proportion of respondents in
the UISCE study reported injecting cocaine than their
counterparts in the Merchant’s Quay study, 58 versus
82 per cent. As Merchant’s Quay provides a needle
exchange facility, this finding was not surprising. 
In the study at Merchant’s Quay, the majority of
injector respondents did not mix the cocaine with
another drug, while 41 per cent mixed it with
heroin (as a snowball). In addition, 30 per cent of
crack users reported injecting crack. As the authors
state, these high rates of injecting cocaine, crack
and ‘speedball’ indicate the high risks taken by this
group. In this study, it was reported that 45 per
cent of crack users and 23 per cent of cocaine users
had not used the drug in the last month but three-
quarters of the respondents reported binge use.
The authors highlighted the high-risk practices
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associated with binge use and stress this is an
important issue for harm minimisation
interventions. Many of the injecting cocaine users
in the study reported a range of mental health
problems, such as, depression and hallucinations.
The authors stated that it was unclear whether the
difficulties experienced by cocaine/crack users were
due to intravenous heroin or cocaine use as 87 per
cent of cocaine injectors were also using heroin.
These issues were not reported for the cocaine
users that participated in the UISCE study. 
In the Merchant’s Quay study, only 44 per cent of
respondents said that their cocaine use was
problematic, and of these, only 16 per cent had
sought treatment. In contrast, three fifths of
respondents in the UISCE survey felt that their
cocaine use was problematic as almost all (98%)
had experienced changes in behaviour since they
started using cocaine. Despite this, only a small
proportion of these (less than one third) had
sought treatment. According to the authors, low
levels of treatment seeking were related to the
belief among cocaine users across both studies that
treatment for cocaine use was futile due to the lack
of a pharmacological substitute. 
The authors reviewed approaches to treatment and
some important issues were highlighted. The
authors emphasised the need to attract problem
cocaine users into services and the need to
empower them to make lasting change. They
found that the most effective method of achieving
this was ensuring that there were no delays in
starting treatment by providing early appointments.
According to the authors, assessments to classify
the severity of the problem were essential in order
to provide appropriate treatment. For example,
providing outpatient programmes for moderate
problems and providing residential programmes for
complex cases were more likely lead to a successful
outcome. The authors reported that the most
effective methods of treating cocaine users were
individual drug counselling, group therapy and
counselling, self-help groups and peer leadership.
The authors stated that treatment services need to
cater for the wider spectrum of illicit drugs used
rather than problem opiate use per se.
Finally, the authors emphasised the need for drug
treatment agencies to establish services orientated
toward the needs of cocaine and polydrug users. The
report described two distinct groups of cocaine users:
cocaine users who never used heroin, and existing
heroin users. The non-heroin users perceive the drug
as clean and acceptable with minimal health
implications. The perception of cocaine as a safe drug
needs to be tackled given the risk behaviours
associated with administering the drug, which
increase when it is used in combination with alcohol
and other drugs. (Fionnola Kelly and Jean Long)
An overview of cocaine use in Ireland is available on
the National Advisory Committee on Drugs website
at www.nacd.ie
1 National Advisory Committee on Drugs (2003) An Overview
of Cocaine Use in Ireland. Dublin: NACD
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Drug seizures down by thirty-nine per cent
The Annual Report of An Garda Síochána for 2002
was published in January 2004. The report is the main
source of information on crime in Ireland. It includes
information on crimes reported to and recorded by
An Garda Síochána and in which criminal proceedings
are taken. The report includes a specific chapter on
drug offences. This details information such as the
number of drug offences in which proceedings were
taken, by police division and drug type, particulars of
drugs seized, the number, age and gender of persons
charged as well as the nature of the offence.
Drug seizures are considered as indirect indicators
of the supply and availability of drugs. As the
quantities of drugs seized can vary significantly over
time the number of separate seizures is regarded as
a more useful indicator. Figure A looks at drug seizure
trends for a selection of drugs between 1998 and 2002.
We can see that there was a 39 per cent drop in the
total number of drug seizures in 2002, down from a
total of 9169 seizures in 2001 to 5603 seizures in 2002.
This drop appears to have been caused by a 51 per
cent decrease in cannabis seizures and a 31 per cent
drop in seizures of ecstasy. One of the key performance
indicators under the supply reduction pillar of the
National Drugs Strategy 2001 – 2008 is to ‘Increase the
volume of opiates and all other drugs seized by 25% by
end 2004 and by 50% by end 2008 (using 2000
seizures as a base)1. 
Figure A also shows, however, that over the same
period, cocaine seizures have increased by 55 per
cent, from a total of 151 seizures in 1998 to 429
seizures in 2002. Amphetamine seizures also
increased during 2002. 
The Annual Report 2002 is the first year when the
full impact of the new Garda information
technology system PULSE (Police Using Leading
Systems Effectively) is seen in the statistics. For
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example, tables are presented outlining outcomes
not only for what the Gardaí describe as ‘headline’
drug offences, but also more information is provided
than heretofore regarding ‘non-headline’ drug
offences. These terms are generally used to
distinguish serious from less serious offences. As most
drug offences fall into the ‘non-headline’ category
and are dealt with summarily in the district court,
the new format enhances the overall picture as to
how drug offences are prosecuted in the courts.
In 2002, the total number of drug offences in which
criminal proceedings commenced was 7,976. Three-
quarters of these (75%) were for simple possession2
while one in four (19%) were for drug dealing.3 Of
the ‘headline’ drug offences in which criminal
proceedings commenced (N=1800), approximately
15 percent led to a conviction on indictment (i.e
before a jury). Of the 6,176 ‘non-headline’ drug
offences in which criminal proceedings commenced,
just over 32 per cent led to a conviction.
The report also provides information on drug
offences where proceedings commenced, by drug
type. In 2002, approximately 65 per cent of drug
offences where proceedings commenced were
cannabis-related, 10 per cent were heroin-related
and approximately 5 per cent related to cocaine.
Figure B shows trends in offences where
proceedings commenced by drug category
between 1998 and 2002. We can see a steady
increase in cannabis-related prosecutions since
1998 and a decline in ecstasy-related prosecutions
since 2000. Heroin-related prosecutions appear to
have fluctuated from year to year, while cocaine-
related prosecutions increased in 2002.
Despite recent improvements in the Annual Report,
a number of shortcomings in the compilation and 
presentation of official crime statistics have been
identified.4 Such problems are not confined to the
Garda statistics alone but cut across the criminal
justice system in general. The statistics are silent on
the number of drug arrests which take place; we
cannot track the course of prosecutions through
the system or identify the nature of sentences
passed. Action Four of the National Drugs Strategy
identifies this as an issue requiring attention during
the lifetime of the strategy. It is one of the matters
currently being investigated by the Expert Group
on Crime Statistics, which is due to report to the
Minister for Justice, Equality and Law reform later
this year. (Johnny Connolly)
The Annual Report of An Garda Síochána for 2002
is available on the Garda website at www.garda.ie
1 Government of Ireland (2001) Building on Experience:
National Drugs Strategy 2001 – 2008 p109.
2 Section 3 Misuse of Drugs Act, 1977.
3 Section 15 Misuse of Drugs Act, 1977.
4 For a recent consideration of this issue see Dr Ian O’Donnell
‘Flawed Garda figures fail to give insight into crime’ Irish
Times 3rd February 2003.
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National Drugs Awareness Campaign
hits the road
On 25 January the Minister for Health and Children,
Micheál Martin TD, launched the second phase of
the National Drugs Awareness Campaign. A key
initiative for 2004 is the ‘Drugs. There are answers’
Roadshow, which will be travelling to major
population centres over the coming months
providing people with the opportunity to meet with
experts and to discuss all aspects of drugs misuse. In
each centre the Roadshow will be backed by local
press and radio advertising. A pilot for the
Roadshow was successfully carried out in Clonmel,
Co Tipperary, last November. A full schedule of the
Roadshow will be announced shortly.
In addition to the Roadshow a month-long burst of
television advertising will begin on RTE1, Network 2,
TV3, TG4, Sky One, Sky News, Sky Sports and E4.
Speaking at the launch, Minister Martin said ‘Our
current campaign forms part of a three-year
campaign, aimed at ensuring that people know that
information and help is available. It is also designed
to ensure people know that such information can
play an important role in dealing with drugs.’
Launched last May, the National Drugs Awareness
Campaign is an important component of the
Government’s National Drugs Strategy 2001-2008.
The overall aim of the Strategy is to reduce
significantly the harm caused to individuals and
society by the misuse of drugs through a concerted
focus on supply reduction, prevention, treatment
and research. A key objective in support of this aim
is to promote throughout society a greater
awareness, understanding and clarity about the
dangers of drug misuse.
The Drugs Awareness Campaign has published two
information booklets: A parent’s guide to drugs and
How do I talk to someone about drugs?. Both
publications are aimed at creating a greater awareness
and promoting communication and openness about
drugs. They can be obtained free-of-charge by ringing
the campaign information line on 1850 719 819. In
addition, individuals wishing to speak confidentially to
someone about their drugs problem can ring this
number to be transferred directly to a Drugs Helpline
staff member. (Hamish Sinclair)
Further information is available on the National Drugs
Awareness Campaign website at www.drugsinfo.ie
In Ireland there is very little published information
that documents clients’ satisfaction with
methadone treatment services. This review presents
the results of two studies. O’Connor1 collected her
data in 1999 while UISCE2 collected their data in
2003. 
O’ Connor examined patient satisfaction with the
pharmaceutical aspect of methadone treatment
services provided between July 1998 and March
1999 using both quantitative (cross sectional survey,
n=217) and qualitative techniques (combination of
group and individual interviews, n=15). She
acknowledges some limitations to the generalisability
of her study due to the sampling methods.
According to the author, respondents were pleased
to have access to treatment services, secure free
treatment, and experience an improved standard of
care. The clients expressed dissatisfaction with
several issues. According to the respondents, there
was a lack of choice with respect to substitution
drugs. The respondents also reported that
attendance at methadone treatment services could
be a humiliating experience. Examples included,
having to comply with punitive contracts, and
having to consume methadone in a public place in
pharmacy retail outlets. According to the
respondents, the services provided at drug treatment
facilities were limited with respect to opening hours,
and social and personal support. The respondents
also reported a problem with exposure to fellow
clients that continued to use street opiates and
attended methadone treatment services. 
In October 2003, the Union for Improved Services,
Communication and Education (UISCE) published a
study that examined clients’ experiences and
expectations of methadone treatment programmes.
The study participants were taking long-term
methadone maintenance and lived in the Dublin
area. The researchers used both quantitative
(survey) and qualitative (focus group) approaches
to collect the information. 
The sampling method for the survey, the rationale
for the sample size chosen, and the response rate
were not documented, so the generalisability of the
study cannot be determined. Notwithstanding
these possible limitations, the high levels of
dissatisfaction with Methadone DTF compared with
Physeptone were in line with O’Connor’s study. 
Clients’ satisfaction with methadone
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Focus groups were conducted as part feedback on the
survey results, and part public consultation process.
The number of focus groups and the numbers
attending each of the groups were not presented in
the published report. Several issues emerged from the
focus groups’ discussions: once again, respondents
expressed high levels of dissatisfaction with
Methadone DTF compared with Physeptone;
respondents’ impression of drug treatment service
personnel was that they were impersonal and
uncaring; participants reported over-use of sanctions
by health professionals; respondents said that the
individual pharmacy contracts provide rights for the
retailers but not for the clients; participants questioned
the use of urinalysis as the best method for detecting
illicit drug use; participants questioned the actions of
health professionals based on urinalysis; respondents
reported lack of confidentiality among service
providers; clients reported lack of participation in their
treatment plan, and the absence of an independent
complaints procedure. 
Surprisingly, there were no positive experiences with
the current methadone treatment programme
reported in the document, which indicates a
possible bias in the information presented or in the
manner by which it was collected. Despite potential
bias, the findings of this study indicate that clients
on long-term methadone maintenance want:
■ to participate in their treatment plan and its
subsequent monitoring and evaluation;
■ a service that caters for the other morbidities
associated with problem opiate use, such as
blood-borne viruses and psychiatric disorders; 
■ courtesy from service providers; 
■ an independent body to decide the course of
action in the event of a disagreement. 
It is also apparent that clients taking methadone
maintenance require impartial information on
policy decisions that affect their treatment. The
time delay could explain the increasing levels of
dissatisfaction expressed by the respondents. 
Notwithstanding the limitations of this first study
by drug users, clients reported high levels of
dissatisfaction with aspects of the methadone
treatment services. While the staff that run the
service may be disappointed with the drug users’
perception, these findings could be turned to
opportunity and provide the first step in a
partnership between clients and service providers
to start to address these issues. The process could
be conducted through the ‘service user charter’ in
each health board area that was recommended in
the current National Drugs Strategy 2001-2008.
When addressing these issues it is important to
develop an approach that ensures that rules are
adhered to but which is not, at the same time,
overbearing. (Jean Long)
1 O’Connor S (2002) Pharmaceutical Services for Patients in
Methadone Treatment in Ireland and the Introduction of the
Methadone Protocol Scheme. University of Dublin, Thesis for
the degree of PhD. Available to read at the Library in Trinity
College Dublin.
2 UISCE (2003) Methadone: What’s the Story? Dublin: Union
for Improved Services, Communication and Education
(Internal Publication). 
Clients’ satisfaction with methadone
services (continued)
In October 2003 the Minister for Health and
Children, Micheál Martin TD, launched the fourth
and final phase of the National Alcohol Awareness
Campaign. This final phase is aimed principally at
women and sees the publication of an information
booklet entitled The Little Book of Women and Alcohol.
The booklet targets women between the ages of 18
and 35 years and aims to increase their
understanding of the effects alcohol has on their
bodies, and to clear up any misunderstanding they
may have about alcohol and excessive drinking.
Other initiatives include A Guide to Rethinking Your
Drinking, a booklet intended as a resource for the
general public and also for health professionals who
may wish to stimulate discussion with their clients on
drinking habits and on how to cut down.
The National Alcohol Awareness Campaign has been
run by the Health Promotion Unit of the Department
of Health and Children for the past three years. At
the launch of the final phase Minister Martin said
‘The objective of the campaign was and still is to
increase the public’s awareness of the problem and
generate debate around the issue and the campaign
has been hugely successful in achieving this. Alcohol
is now uppermost on the public health agenda and I
am anxious that it stays there until a reduction in
alcohol consumption has been achieved.’ 
The first phase of the campaign was launched in
February 2001 and used the theme ‘Less is More –
It’s Your Choice’. Aimed at young people, the
message conveyed was that a person gets more out
of life, has more fun, and enjoys better physical
According to the
respondents, the
services provided
at drug treatment
facilities were
limited with
respect to
opening hours,
and social and
personal support
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Final phase of National Alcohol
Awareness Campaign launched (continued)
health if they avoid drinking at an early age and
then drink in moderation rather than binge drink.
The second phase, launched in July 2001, used the
theme ‘Keep Kids Safe from Drink’ and was aimed
at buyers and suppliers of alcohol in an attempt to
make alcohol less easy for under-age drinkers to get
hold of. It set out to counter the culture of
acceptance of alcohol as harmless and the tolerance
that leads people to collude, often without realising
it, with under-age drinking.
The third phase, launched in November 2002, used
the theme ‘Think before you Drink – Less is More’
and highlighted the growing problem of excessive
alcohol consumption or ‘binge drinking’ in the 18-
29 year age group. (Hamish Sinclair)
For further information see the Health Promotion
Unit website at www.healthpromotion.ie
Binge drinking and drinking-related
harm: a European comparison
A recently published Health Promotion Unit
research paper1 examined Irish drinking habits and
the extent to which drinking was associated with
experiences of adverse consequences. Data were
collected in a survey among a national
representative sample of adults aged 18 years and
older, carried out by Lansdowne Market Research
for the Department of Health and Children. Using
face-to-face interviews, 1069 respondents were
asked questions about their drinking habits and
experiences of adverse consequences from
drinking. Fieldwork was carried out in September
2002. Since the survey contained questions similar
to those used in a recent European comparative
survey involving Finland, France, Germany, Italy,
Sweden and the UK, known as the ECAS (European
Comparative Alcohol Study) countries, it was
possible to make a European comparison. Some of
the main findings are presented below.
A large proportion (23%) of the Irish adult
population do not drink any alcohol. This
proportion was three times as high as in the two
Nordic ECAS countries and almost twice as high as
Germany (13%), the highest ECAS country.
However, for the Irish who do drink the reported
annual alcohol consumption per drinker was 12.1
litres, higher than in any ECAS country. While
Ireland held a mid-position with the ECAS countries
in terms of the yearly number of drinking
occasions, Irish drinkers were more likely to indulge
in binge drinking during these sessions. An
expression of the high inclination to binge drink in
Ireland is the fact that, out of 100 drinking sessions,
58 end up in binge drinking for men and 30 for
women, rates which were much higher than in any
ECAS country. These results suggest that among
those consuming alcohol in Ireland, binge drinking
is the norm among men and occurs on about one-
third of the drinking occasions of women.
On average, Irish male drinkers reported 1.2 adverse
consequences per year associated with their drinking
(of a maximum of eight), which was about twice as
high as the ECAS average and higher than in any
ECAS country. Irish female drinkers also experienced
high rates of adverse consequences; rates were
similar to those in Finland but lower than those in
the UK, the two highest ECAS countries. Irish male
drinkers were more likely to experience fights,
accidents and regrettable conduct as a consequence
of their drinking than their ECAS counterparts. A
similar pattern was also found for Irish female
drinkers, with the exception that women in the UK
experienced more fights and accidents.
For Irish women the experience of health problems
(an indicator of problems caused by long-term
drinking) was the lowest in any of the ECAS
countries. Experience of health problems by Irish
male drinkers was also below the ECAS average but
not as low as Italy and Sweden. According to the
authors, this finding ‘may be related to the
concentration of harm in the younger age groups.
If this is the case, there is a risk that more long-
term consequences will emerge in the future.’
The authors conclude that ‘Ireland has a strikingly
high prevalence of binge drinking and alcohol-
related harm. It will be an important challenge to
find preventive measures that can reduce these
problems.’ (Hamish Sinclair)
1 Ramstedt M, Hope A (2003) The Irish drinking culture –
drinking and drinking-related harm, a European comparison.
Health Promotion Unit. 
This paper is available on the Health Promotion Unit website
at www.healthpromotion.ie/uploaded_docs/
Irish_Drinking_Culture.PDF
On 29 January the UK government introduced a
number of amendments to its Misuse of Drugs Act,
1971.1 As a consequence, cannabis has been
reclassified as a class ‘C’ rather than a class ‘B’ drug.
Other class ‘C’ drugs include anabolic steroids,
benzodiazepines and buprenorphine. Possession of
cannabis or cannabis resin will remain an arrestable
offence, although there will be a presumption
against arrest for adults (i.e. those aged 18 or over)
to be determined on the basis of police guidelines
provided by the Association of Chief Police Officers
(ACPO).2 The maximum penalty for possession for
personal use will reduce from 5 years to 2 years
while the maximum penalty for the trafficking of
any class ‘C’ drug will increase from 5 to 14 years
imprisonment, with the maximum penalty for
trafficking cannabis remaining at its current level of
14 years’ imprisonment. The changes will apply in
England, Wales and Northern Ireland. In Scotland,
arrest for the possession of cannabis is not
automatic and depends on the facts and
circumstances of each case.
The changes came about following a
recommendation from the Advisory Council on the
Misuse of Drugs in March 2002. The Council
concluded that although cannabis is harmful, its
classification as a ‘class B’ drug was
disproportionate in relation to its inherent harm,
and to that of other substances, such as
amphetamines, which are class B drugs.
The Government justified its decision on the basis
that ‘an accurate reflection of the assessment of the
relative harmfulness of drugs…would give the
misuse of drugs legislation greater credibility and
enable…a more effective message to be conveyed
to young people about the dangers of misusing
different types of drugs’. Reclassification would also
highlight the Government’s priority to tackle class A
drugs, such as heroin, cocaine and crack cocaine.
The ACPO guidelines suggest that arrest powers
might be used against those who disregard the law
by smoking in a public place, repeat offenders,
those whose use of cannabis causes or threatens to
cause a public order problem or those in possession
of cannabis in proximity to young people, such as
near schools, youth clubs and play areas. Such
people would be arrested and cautioned. However,
it is anticipated that, for most offences of cannabis
possession, a police warning and confiscation of the
drug will be sufficient. Young people under 18 will
receive a more formalised response, such as a
reprimand, final warning and charge. Unlike the
procedure for adults, such procedures will be
administered at the police station.
A study by South Bank University’s Criminal Policy
Research Unit published in March 2002 represented
the first detailed study of the policing of cannabis
in England.3 The study focused on the offence of
possession, drawing on case studies of four police
‘basic command units’ in two police forces. An
examination of custody records and interviews with
police officers and young people were
complemented by national police and court
statistics. The study found that the financial cost of
policing cannabis was approximately £50 million a
year (including sentencing costs) and that this
activity absorbed the equivalent of 500 full-time
police officers. Reclassification of cannabis to a class
C drug would yield some financial savings, the
study concluded, allowing officers more time to
respond to other calls on their time. The main
benefit of reclassification would, however, be non-
financial, in removing a source of friction between
the police and young people. It was anticipated
that there would be a very small decline in the
detection of serious offences, but this should be
offset by the savings in police time.
In Ireland, since 1977, possession of cannabis or
cannabis resin has been treated differently to other
drugs. Possession for personal use is punishable by
a fine on first or second conviction. From a third
offence, possession for personal use incurs a fine
and/or a term of imprisonment up to one year on
summary conviction and up to three years and/or a
fine if convicted on indictment. The reclassification
of cannabis in the United Kingdom has contributed
to a renewed debate as to its legal status in Ireland.
In rejecting suggestions that Irish law should be
changed in this area, on 31 January 2004, Noel
Ahern TD, Minister of State with responsibility for
the National Drugs Strategy stated that, ‘We’re
quite happy with how the law stands…In the UK,
even after reclassification, in theory, you can still
get a tougher prison sentence than here, so in
many ways they are more or less coming into line
with how we are.’4 (Johnny Connolly)
1 UK Home Office Circular 005/2004 Controlled Drugs.
2 Association of Chief Police Officers of England, Wales and
Northern Ireland 12 September (2003) Cannabis
Enforcement Guidelines. London: ACPO
3 May T, Warburton H, Turnbull PJ and Mike Hough (2002)
Times they are a-changing: Policing of Cannabis. York: Joseph
Rowntree Foundation
4 Where the grass is greener The Irish Times 31 January 2004.
Reclassification of cannabis in the UK
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In Ireland the only published data on compliance with
treatment for hepatitis C is a small on-site hepatitis C
treatment pilot study that was commenced at the
Drug Treatment Centre Board, in liaison with the
infectious diseases unit in St James’s Hospital. On 10
December, Dr Shay Keating presented the results of
this pilot study that examined the potential for
‘treating hepatitis C at the same location at which
clients receive their methadone with a view to
retaining the patients in treatment.’ Dr Keating
cautioned that any centre providing hepatitis C
treatment required referral pathways to specialist
hepatology and psychiatric care. Access to psychiatric
care is required because many of those with hepatitis C
may have a history of psychiatric illness, and
depression is a side effect of interferon (one of the two
drugs used to treat hepatitis C). The specialist
hepatology care included the services of a nurse-
specialist and a medical officer. Nine patients
commenced treatment during the study period and to
date only one has defaulted. Dr Keating concluded
that hepatitis C treatment in drug treatment centres is
ideal as it improves patient compliance and permits a
rapid response to incidences of illicit drug use and
psychiatric illness. Hepatitis C treatment alongside
methadone treatment was also more convenient for
clients. He also said that increased treatment costs at
the drug treatment centres could be offset by reduced
costs at hospital level. It should be noted that the study
methods would have been strengthened by the
inclusion of larger numbers of subjects and the
recruitment of a comparison group receiving treatment
through a specialist centre. (Jean Long)
The complete presentation is available on the 
Drug Treatment Centre Board website at
www.addictionireland.ie. 
Keating S (2003) 0n-site treatment of hepatitis C: a
pilot study. Dublin: Drug Treatment Centre Board. 
Opportunities to provide successful
treatment for hepatitis C in drug
treatment centres
Important changes to infectious disease legislation
were introduced on 1 January 2004. The report,
Review of Notifiable Diseases and the Process of
Notification1 recommended these changes. The
Infectious Disease Regulations 1981 were amended to
establish a revised list of notifiable diseases and, for
the first time, their causative pathogen.2 As part of
the revised legislation, laboratory directors as well as
clinicians are required to report the named notifiable
diseases. Hepatitis C is now specified as a notifiable
disease. The changes to the list of notifiable diseases
are consistent with a European Commission Decision
on communicable diseases.3 (Jean Long)
Complete information is available on the National
Disease Surveillance website at www.ndsc.ie. See
the Changes to Notification of Infectious Diseases
section of the site at www.ndsc.ie/IDStatistics/
ChangestoNotificationofInfectiousDiseases/ 
1 Notifiable Diseases Sub-Committee of the Scientific Advisory
Committee, National Disease Surveillance Centre (2001)
Review of Notifiable Diseases and the Process of Notification.
Dublin, National Disease Surveillance Centre. This report is
available on on the NDSC web site at
www.ndsc.ie/IDStatistics/ChangestoNotificationofInfectiousDi
seases/IDfinal.pdf
2 Infectious Diseases (Amendment)(No.3) Regulations (2003)
Statutory Instrument No. 707/1998, Dublin: Stationery Office.
3 Commission Decision of 22 December 1999 on the
communicable diseases to be progressively covered by the
Community network under Decision No 2119/98/EC of the
European Parliament and of the Council (notified under
document number C(1999) 4015)
Hepatitis C becomes a notifiable disease
Hepatitis C explained
Dr Shay Keating of the Drug Treatment Centre
Board, has updated the booklet, Hepatitis C: A Guide
for Drug Users and their Families. The updated booklet
was launched on 10 December 2003. The
information in this booklet is essential for drug users,
in particular injecting drug users at risk of or
diagnosed with hepatitis C. It is also a useful tool for
doctors, nurses and counsellors who educate drug
users about hepatitis C. The booklet is laid out in a
question and answer format that addresses issues
commonly raised by patients and their families. It
provides updated information on the condition itself
and its treatment. The booklet also provides
transparent information on the criteria for entering
treatment and the side effects of treatment. As the
treatment section has been revised substantially, it is
strongly recommended that health service providers,
drug users and their family members access a copy
of the revised booklet. (Jean Long)
The booklet is available on the Drug Treatment
Centre Board website at www.addictionireland.ie or
from Drug Treatment Centre Board, Trinity Court,
30-31 Pearse Street, Dublin 2. 
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Calls for an extended surveillance system
for hepatitis B and hepatitis C
In December 2003, the National Disease
Surveillance Centre published its Annual Report for
2002. This report includes surveillance information
(up to 2001 or 2002) on a number of diseases of
interest to those working with drug users, including
HIV, viral hepatitis, other sexually transmitted
infections and tuberculosis. The HIV data presented
were reported in Drugnet Ireland Issue 9. 
The number of hepatitis B cases continued to
increase, from 342 in 2001 to 458 in 2002. Just
over half of all notified cases were aged between 25
and 34 years and the proportion of male cases was
approximately equal to the proportion of females.
The data collected with respect to hepatitis B do
not include risk factor status, therefore trends in
this infection among injecting drug users cannot 
be ascertained. 
Up to the end of 2003, hepatitis C was not specified
as a notifiable disease and may be reported as
unspecified hepatitis. In 2002, there were 89 cases
of unspecified hepatitis C notified, of whom, 93 per
cent of cases were identified as hepatitis C.
According to data from the Hospital In-Patient
Enquiry Scheme, there were 1,100 hospital
discharges with a principal diagnosis of hepatitis C
and a further 4,985 discharges with a subsequent
diagnosis of hepatitis C between 1999 and 2001.
Taken together, this would indicate a low level of
reporting for hepatitis C. The inclusion of hepatitis C
as a notifiable disease (from 2004 onwards) will
provide data on new cases of hepatitis C in the
general population but will not specify risk
populations (such as injecting drug users). 
Once again it must be stressed that the inability to
analyse hepatitis data by risk populations leads to
poor targeting of interventions and an inability to
comply with the data requirements of one of the
five key indicators (namely, the drug-related
infectious diseases indicator) identified by the
European Monitoring Centre for Drugs and Drug
Addiction. The authors of the report state that
hepatitis surveillance data would be more useful if
an enhanced surveillance system were introduced.
An enhanced surveillance system would include the
specification of risk factors for each case notified
with hepatitis. (Jean Long)
The 2003 Annual Report of the National Disease
Surveillance Centre is available on the NDSC
website at www.ndsc.ie
Opiate dependency continues to be a cause of
morbidity and premature mortality among the
inhabitants of the European Union. Although many
treatment modalities have been used, methadone
therapy (maintenance and detoxification) has
proved most beneficial to date and is the mainstay
of treatment in the Irish setting.
The Working Party at the National Medicines
Information Centre at St James’s Hospital in Dublin
were commissioned by the National Advisory
Committee on Drugs to review the use of lofexidine
and naloxone in the management of opiate
dependence.
A systematic review was undertaken in order to
evaluate the potential usefulness of lofexidine and
naloxone treatment options in the management of
opiate dependency. All available data were retrieved
by means of a comprehensive search of the
published literature. Contact was made with
experts nationally and internationally to evaluate
the practical issues associated with use of these
drugs in a clinical setting. The authors’ findings are
presented by pharmaceutical agent. 
Lofexidine 
According to the Working Party at the National
Medicines Information Centre,1 evaluation of clinical
trials data for lofexidine showed that it appeared to
be at least as
effective as clonidine
and reducing doses
of methadone, the
other treatment
regimens currently
used in the
treatment of opiate
withdrawal. It was
not possible to
define the optimal
dosage regimen for
this indication
because of the lack
of data from clinical
trials but, in general,
Lofexidine and naloxone in the
management of opiate dependence:
increasing choice
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incremental dosing was used, reaching a maximum
of around 2.2mg per day by day three or four, with
gradual tapering-off to zero by day ten.
The authors also reviewed studies of its use in
clinical practice and showed that it was considered
as effective as clonidine for managed withdrawal
but had a better safety profile (that is, lower
number of cases experienced low blood pressure).
Experts have suggested that lofexidine
detoxification requires intensive input from all
members of the drug treatment team and should
be followed up by further treatment to prevent
relapse. Although there were insufficient data to
evaluate its use in specific subgroups, most workers
have suggested that lofexidine was more effective
in younger patients and those who had a shorter,
less entrenched history of opiate use.
The authors reviewed the availability and, where
data were available, treatment outcomes. 
In Dublin, three outpatient treatment centres and
one inpatient facility were offering lofexidine to
clients. Staff at one of the outpatient centres
recorded and analysed the treatment outcome
data. In total, 84 clients (98 cases) participated in
the ten-day treatment regime between December
2000 and December 2002. Successful detoxification
was achieved if the client’s urine was free of opiates
at the end of the programme. Lofexidine was
administered in conjunction with full medical and
counselling support and patients were seen on a
daily basis, including weekends. Following
successful detoxification, patients were offered
naltrexone and counselling to prevent relapse. The
overall treatment completion rate for cases was 38
per cent (37/98). Success was highest among those
stable on methadone (8/10) and heroin smokers
(13/33). Cases that had not yet stabilised on
methadone had a very low success rate (2/14).
There were no serious episodes of hypotension (low
blood pressure). 
According to the authors, lofexidine may be useful
as an additional treatment for managed opiate
withdrawal in Ireland.
Naloxone 
There are two clinical indications for the use of
naloxone: to facilitate withdrawal for opiates and as
part of the management of an opiate overdose. The
review of naloxone in the management of opiate
withdrawals is presented here. (A review of the use
of naloxone in the management of overdose is
presented elsewhere is this issue). 
According to the
Working Party at the
National Medicines
Information Centre,2
naloxone had been
used, with or
without naltrexone,
to effect rapid
opiate withdrawal.
Results of studies
have shown that the
withdrawal occured
earlier and was
more severe with
use of naloxone
compared with
alpha 2-adrenergic agents such as clonidine or
lofexidine. However, it resolved more quickly
leading to an earlier transition to maintenance
antagonistic treatment. According to the authors,
the long-term benefits of rapid withdrawal had not
been compared with those from standard
withdrawal regimens. Data were insufficient to
identify the most appropriate dosage regimen.
The authors reported that a combination
preparation of buprenorphine and naloxone (4:1
ratio) for sublingual use has recently been
developed. It was shown to be effective as a
maintenance treatment for opiate dependence,
while the presence of naloxone reduced the risk of
misuse of the buprenorphine component. Data
were insufficient to identify the optimal treatment
regimen. The combination was shown to be
equipotent to buprenorphine alone. Subutex® is
authorised for use in opiate dependence in Ireland,
but there is no combination of buprenorphine and
naloxone currently authorised. 
There are no published data on the use of naloxone to
effect rapid opiate withdrawal in Ireland. (Jean Long)
Copies of these reports are available on the
National Advisory Committee on Drugs website at
www.nacd.ie
1 National Medicines Information Centre (2003a) Use of
Lofexidine in the Management of Opiate Dependence
Syndrome. Dublin: National Advisory Committee on Drugs.
2 National Medicines Information Centre. (2003b) Use of
Naloxone in the Management of Opiate Dependence Syndrome.
Dublin: National Advisory Committee on Drugs.
Lofexidine and naloxone in the
management of opiate dependence:
increasing choice (continued)
Overdose is common among drug users, in
particular among those who use opiates. The
Economic and Social Research Institute was
requested to provide data from the Hospital In-
Patient Inquiry Scheme (HIPE), in order to ascertain
the number of hospital admissions (using discharge
data as a proxy) classified as overdoses. Data were
requested on the number (per cent) of cases
admitted to an acute hospital with poisoning as a
result of opiates, sedatives, hypnotics, stimulants
and psychotropic agents by drug-dependency status
and recorded on the HIPE between 1996 and 2001. 
The numbers of patients admitted to an acute
hospital (discharge data used as a proxy) having
overdosed were stable at around 2,500 each year
between 1996 and 2001. Overall, a very small
number of cases (49) died during the period under
review. Between two and four per cent of those
admitted with an overdose had a history of drug
dependence. The average number of overdoses
among those with drug dependency was 93 per
year between 1996 and 2000, with a decrease to
59 in 2001. Of those with a history of drug
dependence, 98 per cent were aged between 15
and 64 years, 68 per cent were male, 76 per cent
were treated in the Eastern Regional Health
Authority area and one-third were treated for a
narcotic-related overdose. 
It has been suggested that most deaths from
overdose occur in the community. Between January
1998 and December 2001, the Dublin City and
County Coroners investigated 332 opiate-related
deaths in Dublin. Byrne1 collated and analysed this
data. Over the four years, over two-thirds (67%
224/342) of those who died were between 15 and
34 years old and the majority (87%) were men.
Fifty-six per cent were alone when they died. Over
half died in their homes and 16 per cent died in a
public space. 
When cross-referenced with other sources of
mortality data (the Coroners’ Office and the Central
Statistics Office), incidence of death once the
person was admitted to hospital was very low. This
suggests that the highest risk of mortality occurs
prior to reaching hospital and indicates that
overdose prevention and management must be
delegated to ambulance crews and possibly to drug
users themselves. 
On the international scene, Sporer2 reviewed the
international evidence on overdose prevention and
reported that heroin overdose has become a
common and preventable cause of death in recent
years. Some combination of increasing treatment
with opiate substitutes, community peer education,
family support groups, supervised injecting
facilities, and making naloxone (the antidote to
opiates) available at home may be needed to have
any practical effect on mortality from overdose. A
number of pilot programmes involving education
of users and distribution of naloxone have begun.
These programmes’ effects on drug-related
mortality, risks and benefits in relation to the use of
use of naloxone, and on patterns of consumption
of heroin by established users and by novices, have
not been reported and should be studied carefully.
The National Medicines Information Centre3
reviewed the use of naloxone in the management
of opiate-dependence syndrome. The authors
reported that naloxone has been used for many
years as an emergency room treatment for the
management of opiate overdose. According to the
authors, evaluation of its use in this setting suggests
that it was associated with a low rate of serious
adverse effects but the data involved small numbers
of patients. Its administration by trained ambulance
staff in the pre-hospital setting resulted in fewer
hospital admissions, but follow-up data on the
patients were lacking in many cases. Although the
availability of take-home naloxone for use by
friends and relatives of an opiate user has been
recommended by several workers, the authors
report that there were no controlled trials
evaluating such usage. Furthermore, records of use
from pilot studies were insufficient to undertake a
benefit versus risk analysis of the use of naloxone in
this setting. However, preliminary results suggested
that it might be of use in these areas. The authors
stressed that naloxone administration was just one
action in a sequence of actions required to prevent
overdose and cautioned against a one-dimensional
approach. They highlight the need for a
combination of the following approaches: 
■ education on the effects of polydrug or
concomitant alcohol use and the usefulness of
naloxone in this situation; 
■ stressing the dangers of solitary injection; 
■ importance of calling an ambulance;
■ knowledge of and practice in basic resuscitation
techniques. 
Further information on the feasibility of naloxone use
as an emergency treatment in the community setting
would be needed before any such programme could
be implemented. According to the authors, there are
many logistical and medico-legal issues that would
need to be dealt with before such a programme
could be implemented in practice.
Taken together, these two reviews present similar
findings and indicate that the management of opiate
overdose requires a multi-dimensional approach,
careful planning and continuous monitoring in order
to learn from experience. (Jean Long)
Multi-dimensional approach required 
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Welcome to the seventh EDDRA (Exchange on
Drug Demand Reduction Action) column. The aim
of this column is to inform people about the
EDDRA online database, which exists to provide
information to those working in the drugs area on
current demand reduction actions across Europe,
and to promote the role of evaluation in the
reducing demand for drugs. The database is co-
ordinated by the European Monitoring Centre for
Drugs and Drug Addiction (EMCDDA). 
At the end of last year there was a total of 463
projects on the database in the areas of drug
prevention, treatment, rehabilitation, harm reduction
and criminal justice. A total of 38 (8%) of these
projects are from Ireland. During 2003 a total of ten
new projects representing good practice in Ireland
were entered into the EDDRA database. A brief
description of each these projects is presented below.
Ana Liffey Children's Project. The project
promotes and supports high-quality parenting and
enhances the quality of life for children of parents
who use drugs.
Rinn Development Drug Rehabilitation Sail
Training Initiative. This initiative offers drug
users an adventure –sailing - that challenges them
mentally, socially and physically.
Tallaght Rehabilitation Project. This project
provides a rehabilitation service to stable drug users
that are receiving methadone treatment at
community-based drug treatment centres.
Merchant’s Quay Outreach Service. This service
was set up to target problematic drug users who
were not linked to any of the mainstream drug
treatment services.
Aislinn Adolescent Addiction Treatment
Centre. This service provides a residential
treatment programme for young people aged
between 15 and 21.
The Labour Market Inclusion Programme.
This project integrates former drug users into the
workplace through offering training and
employment placements.
The Soilse-Rutland Partnership Project. In this
partnership project, Soilse provides the social
rehabilitation and Rutland provides the residential
treatment programme.
The CUMAS Project. Cumas helps families to
cope with the impact of drug misuse on the family
and within the community by offering individual
support services, group work and drug-related
information.
CARP Killinarden Childcare Services. The CARP
childcare service responds to the needs of the
children of opiate-using clients that use the CARP
drug treatment services. 
Health Advice Café. This service provides
information, referral and alternatives to substance
use for young people located in the Western Health
Board region. 
During the months of October and November 2003
the EDDRA website recorded an average of 500
unique visitors per month, with the average length
of each visit lasting between eight and ten minutes. 
More information on these and other Irish projects
can be obtained from the EDDRA website at
http://www.emcdda.eu.int/responses/methods_tool
s/eddra.shtml
Alternatively, you can contact the EDDRA Manager
for Ireland, Mr Martin Keane, at the Drug Misuse
Research Division, Health Research Board, Holbrook
House, Holles Street, Dublin 2. Tel: 01 6761176 or
Email: mkeane@hrb.ie. 
In addition, if you wish to contribute to the
knowledge base of good practice interventions by
adding your own particular project to the database,
then contact the EDDRA Manager for Ireland at the
address above. (Martin Keane)
Thanks are due to Ms Anne Clifton and Ms Aisling
Mulligan for abstracting the data from the HIPE
scheme.
1 Byrne R (2002) Opiate-Related Deaths Investigated by the
Dublin City and County Coroners 1998 to 2001, Briefing No
2. Dublin: University of Dublin, Addiction Research Centre. 
2 Sporer KA (2003) Strategies for preventing heroin
overdose. British Medical Journal, 326: 442-444.
3 National Medicines Information Centre (2003) Use of
Naloxone in the Management of Opiate Dependence
Syndrome. Dublin, National Advisory Committee on Drugs.
(This report is available on the National Advisory
Committee on Drugs website at www.nacd.ie)
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National Documentation Centre 
- first year
In December the National Documentation Centre on
Drug Use celebrated its first year in operation. The
documentation centre was officially opened by Noel
Ahern TD, Minister of State with special responsibility
for drugs strategy, on 9 December 2002. Since then it
has become an essential information resource for
researchers in the drugs area. There are currently more
than 2,200 volumes in the documentation centre
library in Holbrook House, comprising 1,500 separate
titles. The number of titles is growing steadily and
there will be a substantial increase in this figure this
year. The electronic library of research material is easily
accessible through the documentation centre website
and now contains more than 370 full-text documents
comprising journal articles, reports, conference papers,
book chapters and theses. More than 13,000 copies
of these documents were downloaded by visitors to
the website during 2003.
Interest in the various information services provided by
the documentation centre has grown steadily since it
opened. There is an average of 860 visits to the
website every week with each visitor spending an
average of 13 minutes availing of the various
information resources it supports. These include a news
section which currently contains over 800 separate
items with several new items being added every day.
The numbers registering as users of the website
surpassed expectations and there are now more than
300 registered users. National Documentation Centre
staff dealt with over 700 queries during 2003. Staff
carried out literature searches for users of the service,
supplied documents, arranged inter-library loans and
provided expert advise on a huge range of research
topics. Visitors can undertake literature reviews using
the library’s excellent online databases or by searching
the collection of electronic journals available.
The documentation centre is planning major
additions and enhancements to its services over the
coming months. A monthly electronic newsletter
will be delivered directly to users’ desktops and will
provide information on, and links to, recent
publications and current news stories and will also
include tables of contents of journals from which
users can select articles to be delivered to them.
The Current Research and Evaluation Database will
be launched shortly and will become a highly
valuable source of information for those carrying
out or commissioning research or evaluation work
in the drugs area in Ireland. (Brian Galvin)
For further information on theses resources contact
the National Documentation Centre on Drug Use,
Health Research Board, Holbrook House, Holles
Street, Dublin 2. Tel: 01 6761176, Email:
ndc@hrb.ie or visit the website at www.hrb.ie/ndc
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Tommy Larkin established the first drug-users’ forum in Merchants
Quay Ireland and was a co-ordinator with the Union for Improved
Services, Communication and Education (UISCE) Tommy, whom I first
met in 1995, had an almost encyclopaedic knowledge of the history of
drug use in Ireland and he recently played a central role in ensuring
that drug users were provided a voice in ongoing drug policy. In his
descriptions of the drug-using experience, Tommy complemented his
in-depth knowledge with humility, compassion and humour. His advocacy of the interests
of drug users was not grounded in sentimentality but reflected his sense of justice. At
another level, through publications such as Brass Munkie, Tommy used his artistic talents
to encourage awareness and harm reduction practices within the drug-using community.
On the last occasion we met, Tommy talked favourably about the meetings held with
drug service users in Liberty Hall on the impact of the Methadone Protocol. One of the
outcomes of that process, UISCE’S recent ground-breaking study, Methadone: What’s the
Story, portrays Tommy’s understanding and vision. Several hundred drug-service users
attended the Liberty Hall meetings and participated in the surveys that formed the
basis for that study. Providing such a voice to the marginalised was a focus of Tommy’s
work over the past ten years. As Irish society learns to listen to that voice, so his legacy
will be realised.  (Johnny Connolly)
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Expert meeting on drug-related 
infectious diseases
Cited from Lucas Wiessing, Drugnet Europe No. 44,
November–December 2003
Experts from all current and future EU Member
States met in Lisbon from 20–21 October for a
meeting on drug-related infectious diseases. The
general aim of the meeting was to investigate ways
to improve the surveillance of blood-borne
infections (hepatitis B and C, HIV) among injecting
drug users (IDUs).
Three complementary approaches were discussed
at the meeting to improve current data availability,
comparability and quality:
■ To make better use of the drug treatment system
for surveillance purposes and for improving
coverage of screening and access to antiviral
treatment (this entails developing a core set of
behavioural items and good practice guidelines);
■ To investigate the feasibility of collecting HCV
test results from public health laboratories at EU
level, using a very minimal core data set, and if
possible, with recognition of first positive tests;
■ To develop an EU consensus protocol, or ‘tool-
kit’, for new seroprevalence and incidence
studies, and for providing a framework for
combined data analyses of existing studies.
Despite limited resources, the EMCDDA, in
collaboration with its partners, aims to develop these
three areas through working groups composed of the
meeting participants and other interested experts. 
Progress in drug population surveys in the EU
Cited from Julián Vicente, Drugnet Europe No. 44,
November–December 2003
Good-quality population surveys on drugs are a key
source of information for assessing the drug
situation and planning and evaluating national
drug strategies. Recent positive developments in
this area have been the launching of comparable
national population surveys in some Member
States, and the repeating of surveys in others, in
order to help gain an insight into the prevalence,
incidence and patterns of drug use in Europe.
The first prevalence survey of households in Ireland
and Northern Ireland was carried out recently in line
with criteria set by the EMCDDA’s key indicator on
population surveys, developed in collaboration with
a European network of national population surveys.
The increased number of countries now conducting
comparable population surveys means that we now
have at our disposal an ever more comprehensive
picture of the European drug situation. (Brigid Pike)
Drugnet Europe
Drugnet Europe is the bimonthly newsletter of the
European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA). The Lisbon-based EMCDDA
is an autonomous agency of the European Union
established in 1993 to provide the Community and
its member states with ‘objective, reliable and
comparable information’ on drugs and drug
addiction. An electronic version of Drugnet Europe
is available from the EMCDDA’s web site at
www.emcdda.org
If you wish to have your name included on the
mailing list for Drugnet Europe, please send your
contact details to: Drugnet Ireland, Drug Misuse
Research Division, Health Research Board, Holbrook
House, Holles Street, Dublin 2. Tel: + 00 353 1 676
1176, ext. 160; Email:mdunne@hrb.ie 
Drugs in Focus - Policy Briefings
From Drugnet Europe
No. 10: Drug use amongst vulnerable 
young people
There is an urgent need to investigate and monitor
drug use and vulnerability factors among young
people who may be at significantly greater risk of
developing chronic drug problems. The 10th in the
EMCDDA’s series of policy briefings states that, while
experimentation with drugs is increasingly
widespread among young people in Europe, levels of
drug use and the risks of developing drug-related
problems are much higher among vulnerable groups. 
Research has identified a range of risk factors for
developing drug problems. Some risk factors are
associated with characteristics of the individual while
others are linked with family or neighbourhood
characteristics. These factors are highly interconnected
and are best understood as a ‘web of causation’.
According to the briefing, groups of young people
vulnerable to developing drug problems – and
settings where young people are most at risk – are
rarely identified explicitly in national drug-
prevention strategies. Universal, school-based
prevention programmes are in place in most
European countries. However, these do not address
the specific needs of young people most vulnerable
to becoming problem drug users. The briefing
stresses that selective prevention that seeks to
address the needs of vulnerable groups is a vital
complement to universal prevention programmes.
The briefing notes that recent European policy
Drugs in Focus - Policy Briefings
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documents have called for targeted, evidence-
based action to reduce risks, and notes exceptions
to the universal approach to prevention, including
Ireland’s Youthreach and Springboard projects.
In calling for selective intervention strategies, the
policy briefing calls for:
■ information exchange between European
countries on effective practice in addressing the
needs of groups with specifically defined
vulnerability factors;
■ effective targeted programmes, which avoid
contributing to negative labelling, through good
communication between services and agencies
and the insertion of drug prevention into
umbrella social policies; and 
■ rigorous evaluation of the outcome of selective
prevention programmes to ensure that projects
achieve their objectives and to check there are no
unforeseen negative consequences. 
No. 11: Hepatitis C: A hidden epidemic
Subtitled ‘a major challenge to public health’, the
11th policy briefing from the EMCDDA suggests
that, although the total number of people within
the EU infected with hepatitis C is unknown, it is
likely that it exceeds one million and could be
considerably higher. Hepatitis C is a highly
infectious and potentially fatal disease that attacks
the liver. Yet people who have contracted the virus
often remain symptom-free for many years and
most cases are undiagnosed.
On a positive note, the briefing records that, since
the introduction of screening of blood and blood
products for hepatitis C, transmission of the virus
has been ‘dramatically reduced’. Injecting drug
users are now the group at greatest risk of
infection, accounting for up to 60–90 per cent of
new infections. 
The briefing argues for health promotions that
discourage people from injecting drugs or that
change their behaviour to reduce the risk of
contracting the virus. Public and professional
awareness of the disease also needs to be raised to
encourage people at risk to come forward for
testing and referral for treatment where appropriate.
Referring to the drugs challenge posed by EU
enlargement, the briefing states: ‘Young and new
injectors are at high risk of contracting hepatitis C
shortly after they begin injecting. Wherever injecting
drug use is likely to increase, such as some of the
new EU Member States, new epidemics of hepatitis
C are likely to emerge.’ 
The briefing document identifies six policy priorities: 
1 It is important that policy-makers acknowledge
the future impact of hepatitis C infection and
place prevention and treatment of the disease
high on the policy agenda.
2 All EU States face escalating costs due to the
hidden hepatitis C epidemic. Each year of delay
in preventing new hepatitis C infections in the EU
may lead to an increase in treatment costs of an
additional 1.4 billion Euro.
3 The risk of transmission of hepatitis C can be
reduced through measures to alter high-risk
behaviour such as sharing needles and other
injecting equipment, as well as through action to
reduce injecting drug use.
4 There is a short window of opportunity for
prevention with young and new injectors. It is vital
that interventions are targeted at this group, and
at new populations where drug injecting may be
spreading, including in the new member states.
5 Improved screening and monitoring systems for
hepatitis C infection would help ensure that people
needing treatment for hepatitis C are identified
early. They would also enable both trends in
hepatitis C infection and the effectiveness of
preventative strategies to be monitored. 
6 There is a need to review treatment guidelines for
hepatitis C and to develop strategies for
interdisciplinary co-operation between
hepatologists and addiction specialists to include
drug users in treatment. (Brigid Pike)
In just four pages, the Drugs in Focus policy
briefings address a specific theme and include the
latest findings and statistics, key policy issues and
considerations, web information and further
reading. The entire Drugs in Focus series may be
downloaded from the EMCDDA website
(www.emcdda.org). 
Alternatively, if you would like to receive a hard
copy of the current or future issues, please contact
Mary Dunne, Administrative Assistant, Drug Misuse
Research Division, Health Research Board, Holbrook
House, Holles Street, Dublin 2, Tel: + 353 1 676
1176, ext 160, Email: mdunne@hrb.ie
Prevnet Conference
The second annual Prevnet Conference of
Telematics in Addiction Prevention was held in Naas
on 23-25 October. Prevnet is a network of
European organisations who have a shared interest
in promoting the use of telematics for the
prevention of the misuse of drugs and other
substances. These organisations bring a broad
range of experience and expertise to the work of
Prevnet in the areas of health education,
prevention, addiction treatment, information
services, training and research. Among its recent
initiatives is PrevNet Quality, an online tool for
testing websites concerned with the prevention of
drug abuse and related fields. This year’s
drugnet Ireland
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conference included sessions on evaluating
telematic drug prevention, online drug information
and help services, and online counselling. The
session on drug-related websites included a paper
on online pharmacies by Dr Paolo Deluca of St
George’s Hospital Medical School in London. 
Dr Deluca’s Pychonaut Project is attempting to
catalogue the several thousand websites currently
offering drugs normally only available on
prescription. Representatives from all EU member
states attended the conference, which was opened
by Tim O’Malley TD, Minister of State at the
Department of Health and Children. (Brian Galvin)
More information on the conference on the work of
Prevnet is available on the Prevnet website at
www.prevnet.net.
Prevnet Conference
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Books
Living with heroin: Identity, social exclusion
and HIV among the Russian-speaking
minorities in Estonia and Latvia
Downes P Legal Information Centre for the
Humanities, Tallinn; Educational Disadvantage Centre,
St Patrick’s College, Drumcondra, Dublin 2003
ISBN 9985 9410 4 7
This book explores the inner world of heroin users
in Tallinn, Estonia. Between 1999 and 2000
university students conducted 27 intensive,
standardised open-ended interviews with mainly
Russian-speaking heroin users concerning their
emotions and their attitudes to drug taking, social
relationships, and the social world and political
context in which they found themselves.
The research was undertaken in the context of a
pending HIV epidemic in Estonia, the evidence for
which was the exponential rate of increase in hepatitis
B and hepatitis C cases among Russian-speaking
intravenous drug users in Estonia and parallels with
the growth of the HIV epidemic in Odessa in the
Ukraine. The research was intended to help
understand the psychology of injecting heroin users.
The transcripts of the 27 interviews are reproduced
in the book. Author Paul Downes (a lecturer in
educational and developmental psychology at St
Patrick’s College, Drumcondra, Dublin City
University) interprets the interviews from the
perspectives of individual identity and social context.
He argues that traditional neo-Freudian models of
individual identity do not adequately explain the
data: ongoing connection to a parent, usually the
addict’s mother, facilitated rather than hindered
connection to peers, and emotional separation and
distance from parents was associated with a similar
distance in communication with peers. He finds that
among the respondents, the maternal influence
acted as a positive resource for social support and
that, in analysing the heroin addict’s social networks,
there is a need to distinguish between genuine
friends and other peers. He also cites responses that
challenge the view of the addict as a rebel rejecting
society’s values. In the context of Estonia, he
suggests that heroin addiction is not reducible to
explanation simply or even predominantly in terms
of difficult family relationships but frequently involves
issues of social and ethnic identity. 
Reviewing recent research on heroin use and the
incidence of HIV cases in the Baltic states (Estonia,
Latvia and Lithuania), Downes finds that Russian-
speaking minority youth populations in both Estonia
and Latvia display exceptionally high levels
internationally of (a) use of hard drugs at an early age
as first drug of use, (b) rates of increase in use of hard
drugs, and (c) HIV rates. Downes argues that the
current Estonian and Latvian State Integration
Programmes, designed to integrate Russian-speaking
minorities in the two countries, present serious risk
factors for youth from the Russian-speaking
minorities. He argues that these programmes’ narrow
conception of social competence and their focus on
academic achievement have led to a ‘failure identity’
for many among the Russian-speaking minority and
demotivation, which, in turn, increase the risk of
falling into a cycle of social marginalisation, early
school-leaving, heroin use and HIV. 
In conclusion, Downes suggests: ‘A fragmented
approach which ignores the systematic interrelation
between the needs of less academic students, early
school leavers, heroin addicts and those at risk of HIV,
both in Estonia and Latvia, needs to be overcome.’
Prescribing heroin: What is the evidence?
Stimson GV and Metrebian N Joseph Rowntree
Foundation 2003
ISBN 1 85935 028 8
The authors of this publication claim that the UK is
one of only three countries where heroin is
included in the range of legally sanctioned
treatments for opiate dependence (of recent date,
Switzerland and the Netherlands have authorised
the prescription of heroin in strictly limited
circumstances). Prescribing heroin presents an
overview of how and why heroin is prescribed in
the UK, and brings together research evidence from
the UK and elsewhere to provide a comprehensive
review of its benefits and drawbacks. Currently, a
small number of UK doctors prescribe heroin (to
some 448 users) and the government is planning a
cautious and modest expansion of this treatment.
The authors point out that the evidence base for the
effectiveness of heroin as a treatment is rather
limited, and highlight some of the problems in
conducting research in this area. Based on the
available evidence, the study considers whether
heroin prescription is effective in the short and the
long term. This overview covers: the reasons put
forward for prescribing heroin, and why the
expansion of this treatment is being considered; the
history of prescribing heroin and how the practice
and goals of prescribing have changed over time;
how illicit heroin is manufactured and used, and the
harms associated with its use; current approaches to
heroin problems in the UK; the range of services
and interventions provided for heroin users. It
concludes with a summary of the research, clinical,
political and practical challenges for expanding
heroin prescribing in the twenty-first century.
Addiction and change: how addictions
develop and addicted people recover
DiClemente C The Guilford Press 2003
ISBN 1 57230 057 4
This book is presented as a practical guide to help
clinicians, prevention specialists, policy makers and
students navigate their way through competing
theories, data and dogma on how addiction can best
be prevented and treated. It deals with such diverse
problems as nicotine dependence, alcohol and other
drug abuse, compulsive gambling and eating
disorders, and begins with a review of traditional
theories of addiction and the research supporting
them. DiClemente makes the case that
inconsistencies in society’s attitudes to addictions give
rise to policies ranging from prohibition and
criminalisation to hospitalisation and mandated
treatment – all of which, in his view, have serious
shortcomings. The author’s premise is that both
addiction and recovery can be managed more
effectively when viewed as a process of behaviour
change. The book addresses the problem of addiction
in terms of the Transtheoretical Model (TTM) of
intentional behaviour change (co-developed by
DiClemente and refined in his research and writings
over the past 20 years). He points out that addictions
are multi-determined and take hold over time, and
that recovery is also a journey that takes time and
effort and is often filled with false starts and failed
attempts. While the factors that lead a particular
individual into addiction and out of it are unique to
that individual, the process of becoming addicted
and of recovery follow a common path – a
continuum of addictive behaviour change. 
The book is organised into four parts. Part I
introduces addiction and recovery as a process of
change; it gives the historical perspective to addiction
theories, describes the current understanding of the
process of behaviour change as embodied in the
TTM, and details the fully developed final stage in the
path to addiction, which is, at the same time, the
starting point of the stages of recovery. Part II deals
with the behaviour changes involved at different
stages on the road to addiction. Part III describes in
detail each of the stages of recovery, discusses the
critical goals and tasks of each stage, and outlines
how the change dimensions of the TTM interact in
the transition from one stage to the next. Part IV
addresses prevention and treatment, discussing ways
to tailor interventions more effectively to people at
different points in the change process. The final
chapter examines several broad areas of intervention
and evaluation research and explores how the TTM
can contribute to current topics such as cultural
competence, pharmacological treatments, harm
reduction and dual diagnosis. 
The politics and economics of drug production
on the Pakistan-Afghanistan border
Amir Zada Asad, Harris R
Ashgate, 2003
ISBN: 0-7546-3037-4
This book examines the socio-economic and political
factors which have led to an explosion in opium
production in Pakistan’s North Western Frontier
Province (NWFP) over the past twenty-five years.
Pakistan now contains 25 per cent of the world’s
heroin addicts and each year 100,000 new addicts
are reported. The NWFP region also supplies much of
Europe’s heroin. The mountainous NWFP is the
poorest of Pakistan’s four provinces, with little
agriculture or industry to support its population of
almost 16 million. One of the authors, Amir Zada
Asad, is a tribesman from the region and was able to
do the type of fieldwork which would have been
impossible for an outsider. Opium production is
important to NWFP farmers as it produces yields
between three and ten times higher than other crops.
Besides these economic factors, the authors highlight
three important political events which contributed to
the narcotics boom: the Hudood Ordinance; the
Soviet intervention in neighbouring Afghanistan; and
the Iranian revolution. In 1979 under pressure from
the UN to outlaw opium production the Pakistani
Government issued the Hudood Ordinance, an
Islamic law that banned the use, traffic and
production of all intoxicants, including opium, and
abolishing the centuries-old vend system. However, it
did not ban heroin, and Pakistan’s existing opium-
using population became a captive market for heroin.
Others, including Alfred Mc Coy, have highlighted
the CIA involvement with the Mujahideen and drug
trafficking in neighbouring Afghanistan. Iran for
centuries had imported opium to satisfy its large
addict population and also served as a base for
opium production and trafficking to Western Europe.
With the fall of the Shah and the Iranian revolution
strict anti-narcotic laws forced drug lords to move to
neighbouring Pakistan. These factors combined
meant that by 1981 Pakistan had accounted for 73
per cent of all heroin seized in Europe, the Middle
East, Africa and Central Asia. It also accounts for 90
per cent of all seized heroin in the United Kingdom. 
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Articles
The following are brief summaries of a selection of
articles published in international journals during
2003 and 2004, relating to the drugs situation in
Ireland or written by Irish authors.
Alcohol and drug use amongst young
attenders to A+E
Eager R, Barton D
Irish Medical Journal 2003 Nov/Dec; 96 (10): 
311-312.
The authors carried out a three-month prospective
study of all patients up to the age of thirty years
who attended the emergency department. A
standard questionnaire was completed on young
patients presenting with alcohol or drug use, both
recreational and deliberate self-harm (DSH). All
appropriate attendances were identified by
extraction of patient lists for the study period from
the hospital information system. The study shows
that alcohol and drug use are common causes of
attendance at this emergency department. It
represents a potential cause of significant
morbidity to the young in this catchment
population. In most cases, management of these
patients was uncomplicated. An observation unit
adjacent to the emergency department would
benefit patient and staff alike. 
High morbidity expected from cirrhosis in
injecting drug users
Kavanagh P, MoloneyJ , Quinn C.
Irish Medical Journal 2003 Nov/ Dec; 96 (10): 
303-305
Hepatitis C infection commonly complicates
injecting drug use. The outcome of end stage liver
disease for this cohort in Ireland has not been
estimated. The objectives of this study were: to
estimate the prevalence of persistent hepatitis C
viraemia and distribution of genotypes in a drug
using cohort; to measure the frequency of poor
prognostic co-factors; to extrapolate the burden
of hepatitis C related disease nationally for this
route of infection. A cross section survey of
attendees at an East Coast Area drug treatment
clinic was prepared. Of 94 patients studied (63
male), 70 were hepatitis C antibody positive and
39 were PCR positive. Twenty-six had genotype 1
and 11 had genotype 2 or 3. Most displayed
factors associated with a poor prognosis: 72%
male, 83% problem drinkers and 87% abnormal
liver blood tests. Using published data, we
extrapolate over 1,214 cases of cirrhosis via this
route of infection nationally, leading to
approximately 35, 60 and 50 cases of
hepatocellular carcinoma, hepatic
decompensation and liver related death
respectively per annum. A high prevalence of
hepatitis C infection in injecting drug users,
compounded by a high frequency of poor
prognostic co-factors, means a significant burden
of disease can be expected from this group.
Specialized drug liaison midwife services
for pregnant opioid dependent women in
Dublin, Ireland
Scullya M, Geoghegan N, Corcoran P, Tiernan M,
Keenan E
Journal of Substance Abuse Treatment 2004 Jan; 26
(1): 329-335.
The health needs of pregnant opioid dependent
women are increasingly being recognized by health
care professionals. These women generally receive
limited antenatal care. Maternal and neonatal
outcomes are also poorer compared to non-drug
using women. The number of pregnant opioid
dependent women accessing drug treatment
services in the Irish Republic has increased. A
specialist Drug Liaison Midwife service was created
in March 1999 to liaise between the three Dublin
Maternity hospitals and the Drug Treatment
Services. This paper surveys the first year of
operation of one of these posts. It documents
socio-demographic background, substance use,
and medical histories of these women in addition
to maternal and neonatal outcomes. Higher
maternal methadone dose was associated with an
increased risk of neonatal withdrawals among these
women. The experience of this specialist liaison
service indicates that it is possible to build effective
working relationships between opioid dependent
pregnant women and the Obstetric and Drug
services involved in their care. 
Paying the Price for Extended Opening
Hours: a comment from Ireland
Butler S
Drugs: education, prevention and policy 2003 Nov;
10(4): 293-296.
The author traces the development of Ireland’s
parallel, and contrasting, alcohol-policy processes.
National Alcohol Policy Ireland (1996) contained
no realistic strategy for the implementation of its
proposals to control consumption. The first piece
of licensing legislation, the Intoxicating Liquour
Act 2000, enacted after publication of the national
alcohol policy document made hardly any
reference to this policy. It considerably extended
the opening hours of pubs. The four reports of the
Liquour Licensing Commission, which was set up
by the Minister for Justice, Equality and Law
Reform immediately after the new legislation was
passed, saw alcohol primarily as a commodity to
be distributed according to market principles. The
Interim Report of the Strategic Task-force on
Alcohol (2002) detailed the rapid increase in
alcohol consumption on the years between 1989
and 1999 and the consequent increase in alcohol-
related harm. The Intoxicating Liquor Act 2003
can be seen as a compromise between the
contrasting strands of alcohol policy. It allowed for
a slight reduction in opening hours. However, the
emphasis in the effort to reduce alcohol-related
harm is on combating drunkenness rather than the
use of consumption control measures.
(Joan Moore, Louise Farragher, Damien Walshe)
Recent Publications (continued)
March
4 –5 March 2004
2nd UK National Drug Treatment
Conference 
Venue: Victoria Park Plaza Hotel, London.
Organised by/Contact:
UK National Drug Treatment Conference,
PO Box 36646, London, SE1 9ZT 
t +44 (0)20 7928 9152 
e monique@exchangeconferences.org
w www.exchangesupplies.org/conferences/
UKNDTC/ukndtcsecondconf.html
Information: This will be the most
important drug treatment conference of the
year for drug workers, drug activists, criminal
justice workers, prison healthcare staff,
clinicians, researchers, policy makers, service
providers and commissioners. In order to
support and encourage good practice and
research, abstracts are invited for either oral
paper presentations or poster displays during
the two-day event.
9 – 10 March 2004
Using research to influence drug
communications
Venue: Birmingham 
Organised by/Contact: 
Sonia Russo, Calder Conferences
t +44 (0)113 258 8020
f +44 (0)113 2583344, 
e dcs@caldercom.co.uk
w www.calderconferences.co.uk
Information: This two-day conference will
be an invaluable one-stop shop covering a
wealth of research into the motivations and
behaviour of drug users - combined with
studies on how to communicate/market
drug prevention messages effectively. This
conference is aimed at drugs workers who
are responsible for drafting and delivering
communications strategies on drugs. 
11 March 2004 
Effective Strategies to Tackle Drug-
Related Crime. 
Venue: London
Organised by/Contact: 
Gemma Suter
t +44 (0) 207 324 4363
e gemma.suter@neilstewartassociates.co.uk
w www.neilstewartassociates.com
Information: This national one-day
conference will examine in detail the key
issues in tackling drug-related crime,
including prevention measures, working
with young people, reducing the supply of
drugs, actively engaging the community,
effective treatment and partnership working.  
27 March 2004, 9.30am - 5.15pm 
Drugs: Issues and Experiences
Venue: Purcell House Conference Centre,
All Hallows College, Drumcondra, Dublin 9
Organised by/Contact: Community
Awareness of Drugs, 31/31a Central Hotel
Chambers, Dame Court, Dublin 2. 
t 01 679 2681 
f 01 679 7818 
e communityawareness@eircom.net 
w www.aboutdrugs.ie 
Information:
Principal speakers:
Dr Des Corrigan
Senior Lecturer at the School of Pharmacy,
Trinity College Dublin, and Chair of the
National Advisory Committee on Drugs
Audrey Kilgallon (to be confirmed)
An addiction counsellor at the National
Drug Treatment Centre, Trinity Court, with
vast experience of working with both young
people and their families.
Coolmine Therapeutic Community &
Merchants Quay Ireland
Young people in recovery and
representatives from family support groups
will share their personal experiences.
Cost: Education Day €60 (includes
refreshments and lunch). Certification of
attendance available. To reserve a place
please return the registration form and the
full €60 non-refundable fee to the CAD
office as soon as possible. Bursaries are
available in exceptional circumstances.
April
20 April 2004
15th International Conference on the
Reduction of Drug Related Harm 
Venue: Melbourne, Australia
Organised by/Contact: International
Harm Reduction Association and the
Australian Drug Foundation. 
t +00 61 3 9278 8137 or +00 61 3 9278 8101 
f +00 61 3 9328 3008
e ihrc2004conference@adf.org.au
w www.ihra.net
Information: The theme for the 2004
conference will be ‘Minimising the harm:
maximising the impact’. This theme will run
through every Conference activity – how can
we use our evidence base and our alliances
to change the world? As well as the normal
wide range of topics, speakers and styles of
presentation or discussion, the Conference
will also concentrate on a number of major
themes, including: Policing and harm
minimization;The economics of drugs; Local
government, drug policy and harm
reduction; International treaties; Indigenous
populations, drugs and harm reduction;
Pharmacotherapies; Needle and syringe
exchange and harm reduction; Public health
law and harm reduction; Alcohol and harm
reduction; The media and harm reduction.
The call for abstracts is now open. 
21 – 22 April 2004 
Consensus Conference on Hepatitis C 
Venue: Royal College of Physicians of
Edinburgh, Edinburgh, Scotland.
Organised by/Contact: Margaret
Farquhar, Royal College of Physicians of
Edinburgh, 9 Queen Street, EDINBURGH,
EH2 1JQ 
t +44 (0)131 225 7324 
f +44 (0)131 220 4393 
e m.farquhar@rcpe.ac.uk
w www.rcpe.ac.uk/events/hep_c_04.html
Information:The key questions which a
multidisciplinary panel will aim to answer
from the presented evidence and open
discussion raised during the conference are:
What is the nature of the problem? Who is
at risk and how do we identify them? How
should we manage the patient? What is the
best treatment? What lies ahead and can
we afford it? Abstracts are invited for poster
presentation. 
May
10 May 2004 
Crack Cocaine: patterns of use,
effective services and treatment 
Venue: The Celtic Royal Hotel Caernafon,
Wales
Organised by/Contact:Dianne Lewis
e Dianne.Lewis@nww-tr.wales.nhs.uk 
e info@celtic-royal.co.uk 
Information: A one-day conference
focusing on the epidemiology of crack
cocaine use, treatment options for crack
cocaine and setting up services for
delivering treatment. Sessions include:
physiology and implications for health,
service provision, patterns of use and the
criminal justice perspective. 
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If you have information on upcoming
conferences or other events, please let 
us know so that we can include it in 
future issues of Drugnet Ireland. 
Send information to Drugnet Ireland, 
Drug Misuse Research Division, Health
Research Board, Holbrook House, 
Holles Steet, Dublin 2.
Tel: (01) 676 1176; 
Email: bgalvin@hrb.ie.
